Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Rationality of Use and Effectiveness of Stress Ulcer Prophylaxis in Critically Ill Patients: An Experience from A Tertiary Intensive Care Unit

Journal of Biomedicine and Translational Research · Vol. 8 No. 3 (2022) · hlm. 138–144

DOI
10.14710/jbtr.v8i3.16387
ISSN
2503-2178
Terbit
2022-12-30
Penerbit
Faculty of Medicine, Universitas Diponegoro
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-sa/4.0

Abstrak

Background: Stress-related mucosal disease (SRMD) frequently develops in critically ill patients, increasing mortality and length of intensive care unit (ICU) stay. There is limited data on stress ulcer prophylaxis (SUP) on critically ill patients in Indonesia.Objective:Methods: This is a retrospective cohort study of patients admitted to the ICU from January 1, 2015, to December 31, 2017. The subjects were all ICU patients who used proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) as SUP therapy.Results: A total of 315 patients were included, and mean age was 48 years. Approximately 55.2% were women, and 62.8% of patients were admitted to ICU following high-risk surgery. PPI was given to 187 patients (59.4%) and H2RA to 128 patients (40.6%), with an average usage for 5 days. The incidence of SRMD was 15.9% (n = 50), and mean length of stay in the ICU was 6 days. Gender, age, duration of SUP, and ICU length of stay of the PPI and H2RA groups were not statistically different (p > 0.05) and did not affect the GI event (p > 0.05). The use of rational SUP was 98.4%. Major American Society of Health-System Pharmacists (ASHP) risk factor criterion was ventilator use (86.8%), while the minor ASHP criterion was anticoagulant therapy (22.2%). The incidence of GI event was significantly lower in PPI groups than H2RA groups (p < 0.05).Conclusions: The use of SUP is rational with an average use of 5 days. PPI are superior to H2RA for SRMD prophylaxis.

Kata kunci

Jaringan kolaborasi para penulis

25 penulis · 76 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Diponegoro University
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Tri Ferry RachmatullahDiponegoro University3
Charles LimantoroDiponegoro University3
Fransisca Yustika Dewi SiahaanDiponegoro University1
Khristophorus Heri Nugroho Hario SenoDiponegoro University1
Rakhma Yanti HellmiDiponegoro University1
Etika Ratna NoerDiponegoro University1
Adriyan PramonoDiponegoro University1
R.A. KusumaDiponegoro University1
Choirun NissaDiponegoro University1
Endang MahatiDiponegoro University1
Nani MaharaniDiponegoro University1
Sultana MH FaradzDiponegoro University1
Rayvita AN MeagratiaDiponegoro University1
Ferdy Kurniawan CayamiDiponegoro University1
Udin BahrudinDiponegoro University1
Wiwik LestariDiponegoro University1
Siti Fatimah MuisDiponegoro University1
Risky Ika RianiDiponegoro University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://ejournal2.undip.ac.id/index.php/jbtr/oai, pertama di-harvest 9 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Rationality of Use and Effectiveness of Stress Ulcer Prophylaxis in Critically Ill Patients: An Experience from A Tertiary Intensive Care Unit</dc:title>
	<dc:creator>Purnomo, Hery Djagat</dc:creator>
	<dc:creator>Prabowo, Heru</dc:creator>
	<dc:creator>Permatadewi, Cecilia Oktaria</dc:creator>
	<dc:creator>Hutami, Hesti Triwahyu</dc:creator>
	<dc:creator>Indiarso, Didik</dc:creator>
	<dc:creator>Prasetyo, Agung</dc:creator>
	<dc:creator>Hirlan, Hirlan</dc:creator>
	<dc:subject xml:lang="en-US">upper gastrointestinal bleeding; critically ill; risk factors; proton pump inhibitor; ICU</dc:subject>
	<dc:description xml:lang="en-US">Background: Stress-related mucosal disease (SRMD) frequently develops in critically ill patients, increasing mortality and length of intensive care unit (ICU) stay. There is limited data on stress ulcer prophylaxis (SUP) on critically ill patients in Indonesia.Objective:Methods: This is a retrospective cohort study of patients admitted to the ICU from January 1, 2015, to December 31, 2017. The subjects were all ICU patients who used proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) as SUP therapy.Results: A total of 315 patients were included, and mean age was 48 years. Approximately 55.2% were women, and 62.8% of patients were admitted to ICU following high-risk surgery. PPI was given to 187 patients (59.4%) and H2RA to 128 patients (40.6%), with an average usage for 5 days. The incidence of SRMD was 15.9% (n = 50), and mean length of stay in the ICU was 6 days. Gender, age, duration of SUP, and ICU length of stay of the PPI and H2RA groups were not statistically different (p &gt; 0.05) and did not affect the GI event (p &gt; 0.05). The use of rational SUP was 98.4%. Major American Society of Health-System Pharmacists (ASHP) risk factor criterion was ventilator use (86.8%), while the minor ASHP criterion was anticoagulant therapy (22.2%). The incidence of GI event was significantly lower in PPI groups than H2RA groups (p &lt; 0.05).Conclusions: The use of SUP is rational with an average use of 5 days. PPI are superior to H2RA for SRMD prophylaxis.</dc:description>
	<dc:publisher xml:lang="en-US">Faculty of Medicine, Universitas Diponegoro</dc:publisher>
	<dc:date>2022-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ejournal2.undip.ac.id/index.php/jbtr/article/view/16387</dc:identifier>
	<dc:identifier>10.14710/jbtr.v8i3.16387</dc:identifier>
	<dc:source xml:lang="en-US">Journal of Biomedicine and Translational Research; Vol 8, No 3 (2022): December 2022; 138-144</dc:source>
	<dc:source>2503-2178</dc:source>
	<dc:source>10.14710/jbtr.v8i3</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/view/16387/8431</dc:relation>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/downloadSuppFile/16387/4071</dc:relation>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/downloadSuppFile/16387/4072</dc:relation>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/downloadSuppFile/16387/4073</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2022 Journal of Biomedicine and Translational Research</dc:rights>
	<dc:rights xml:lang="en-US">https://creativecommons.org/licenses/by-sa/4.0</dc:rights>
</oai_dc:dc>